What Cerberus Therapeutics does

Cerberus Therapeutics is a preclinical biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops VHH (variable heavy domain of heavy-chain-only antibody), or nanobody, platforms organized around two distinct programs: a Tolerance Induction platform for autoimmune diseases and a KappaLink platform for infectious diseases. Its technology is based on single-domain antibodies derived from camelid heavy-chain-only antibodies and is positioned for therapeutic applications in immunology and infectious disease indications.

The company was co-founded by Novalia Pishesha, who serves as CEO, alongside scientific co-founders Hidde Ploegh and Harvey Lodish, both researchers affiliated with leading Boston-area academic institutions. It has built a Scientific Advisory Board including Dougan, Hafler, and Hodges, and has added Jim Weissman to its Board of Directors. Reported headcount is 1-10 employees, consistent with its preclinical status and capital base.

Cerberus Therapeutics is currently pre-revenue and pre-commercial, with no clinical-stage assets. It has raised approximately $9 million in disclosed funding across two rounds: a $4 million seed round from Sherpa Healthcare Partners in December 2021, and a $5 million investment from the Bill & Melinda Gates Foundation in December 2023. The company has additionally received Golden Ticket awards from Novo Nordisk (2023), Biogen (2022), and AbbVie-LabCentral (2022), which typically confer lab space, reagents, and access to pharma expertise. As a preclinical company with no approved products, revenue mechanics are not yet established.

Name

Cerberus Therapeutics

Legal name

Cerberus Therapeutics, Inc.

Website

https://cerberustx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Cerberus Therapeutics is a preclinical, Cambridge, MA-based biotech developing proprietary VHH (nanobody) platforms targeting autoimmune disease (Tolerance Induction) and infectious disease (KappaLink). Founded in 2021, it is pre-revenue with approximately $9 million in disclosed funding.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

Keywords

• Nanobody therapeutics
• Autoimmune disease treatment
• Infectious disease therapeutics
• VHH antibody platforms
• Immunomodulation biotechnology

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Licensing and Development Partnerships: Pre-commercial biotech company generating revenue through strategic partnerships with pharmaceutical companies for development and commercialization of nanobody-based therapeutics. Programs in autoimmunity and infectious diseases are in preclinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Cerberus Therapeutics is a preclinical-stage biotechnology company developing proprietary nanobody-based (VHH) immunotherapeutic platforms. Its Tolerance Induction Platform targets MHCII to rewire the immune system toward tolerance in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and ANCA-associated vasculitis. Its KappaLink Platform creates VHH-based adducts that engage polyclonal antibodies and activate complement to provide protective immunity against infectious diseases including influenza, SARS-CoV-2, and HIV.

Product overview

Cerberus Therapeutics is a platform company developing two distinct nanobody-based immunotherapeutic platforms built on alpaca-derived VHH (variable domain of heavy chain-only antibody) technology. The Tolerance Induction Platform targets autoimmune diseases by engaging antigen presenting cells via MHCII to rewire the immune system toward tolerance. The KappaLink Platform addresses infectious diseases by using engineered VHHs that recognize antibody light chains, creating adducts that activate complement and mount protective immune responses. Both platforms exploit the unique biochemical properties of nanobodies—small molecular weight (~1/10 of traditional antibodies), high affinity, rapid tissue penetration, and low immunogenicity—to enable single-dose administration with potential curative outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• Tolerance Induction Platform: A nanobody-based platform that targets MHCII to engage all types of professional antigen presenting cells for immune tolerance induction in autoimmune diseases.
• KappaLink Platform

Products and services

• Tolerance Induction Platform A proprietary nanobody-based immunotherapeutic platform that targets MHCII antigens on professional antigen-presenting cells (dendritic cells, macrophages, B cells) to induce antigen-specific immune tolerance for the treatment of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and ANCA-associated vasculitis.
• KappaLink Platform A proprietary infectious disease platform using engineered VHHs that recognize antibody light chains (immunoglobulin kappa chain), combined with small-molecule antivirals or pathogen-specific VHHs to create adducts that activate complement and engage polyclonal antibodies (IgG, IgM, IgA, IgE) for protective immunity against influenza, SARS-CoV-2, and HIV.
• VHH (Nanobody) Technology Core proprietary alpaca-derived single-domain antibody fragment (VHH) technology with molecular weight approximately one-tenth that of traditional antibodies, high antigen-binding affinity, high solubility and stability, rapid tissue penetration, fast clearance, low immunogenicity, and cost-efficient manufacturing in microbial systems.

Quantifiable outcome

• Single dose administration for minimal toxicity in autoimmune applications
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• argenx: argenx is the leading commercial-stage nanobody (VHH) biotech with efgartigimod approved in autoimmune disease (myasthenia gravis, ITP). It is the most direct comparable to Cerberus's Tolerance Induction Platform because both companies commercialize VHH-derived therapeutics for autoimmune indications.
• AbCellera Biologics: AbCellera operates a technology platform for antibody discovery including single-domain/nanobody workflows with pharma partnerships. Comparable to Cerberus as a platform company monetizing VHH-enabled drug discovery through partnerships.
• Selecta Biosciences: Selecta developed antigen-specific immune tolerance therapies (ImmTOR platform) for autoimmune disease and gene therapy immunomodulation. Directly comparable to Cerberus's Tolerance Induction Platform, which similarly aims to rewire immune responses against specific antigens.

Emerging players

• Anokion: Anokion is a clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases (celiac, MS). Comparable to Cerberus's autoimmune tolerance approach via a different molecular strategy (protein-engineered antigens vs. VHH-MHCII targeting).
• Eligo Bioscience: Eligo Bioscience is a preclinical/early-clinical biotech using engineered payloads (including nanobody-based phage-derived particles) to modulate the microbiome and immune system. Overlaps with Cerberus's nanobody-based immune modulation approach in an emerging modality niche.
• Crescendo Biologics: Crescendo Biologics develops T cell engagers built on a humanized VHH (Humabody) domain platform for cancer and autoimmune disease. Comparable to Cerberus because both commercialize VHH domain-based therapeutics targeting immune cells.
• Compass Therapeutics: Compass Therapeutics is a clinical-stage immuno-oncology and autoimmune biotech with antibody platforms including bispecifics. Comparable to Cerberus as a small-cap immunology platform company with partnership-driven business model.
• Adagene: Adagene is a clinical-stage biotech using antibody engineering and masking technologies (POWERbody and SAFEbody platforms) to develop targeted immuno-oncology therapeutics. Comparable as a small-cap antibody-engineering platform company pursuing partnered clinical development.
• Merus: Merus is a clinical-stage oncology biotech developing bispecific antibody therapeutics (Biclonics and Triclonics platforms). Comparable to Cerberus as a smaller-cap engineered antibody platform company with partnership-licensed assets.

Broad incumbents

• Sanofi (Ablynx): Sanofi acquired Ablynx in 2018 for its nanobody platform (now marketed as ozanimod-class franchises and internal VHH programs). Comparable to Cerberus as the broad incumbent that established nanobodies as a commercial modality, defining both the opportunity and competitive ceiling for VHH biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cerberus-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerberus Therapeutics